Innovation Medicine burst out! Is Sansheng pharmaceutical expected to gain more profits?

Wonderful content recently, Sansheng pharmaceutical announced that baidayang ® was officially approved by CFDA and became the first long-acting GLP-1 receptor agonist approved in China for the treatment of type 2 diabetes In addition, as a leading enterprise in the domestic biopharmaceutical industry, Sansheng pharmaceutical has a market leading biopharmaceutical product line in oncology, autoimmune diseases and nephrology Its products include tebio, ibio, ipsai, etc., and it also maintains the leading position in the domestic market   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> the first long-acting GLP-1 in China has been approved for marketing this time The long-acting GLP-1 (glucagon like peptide-1) approved for marketing by Sansheng Pharmaceutical Co., Ltd is a kind of hypoglycemic drug that can be administered once a week Its trade name is bydureon ®, and its general name is exenatide microspheres for injection, which is used for the treatment of type 2 diabetes It is the first long-acting GLP-1 receptor agonist approved in China At present, five GLP-1 receptor agonists have been approved for marketing in China, including BCP (exenatide) and BDP (exenatide microspheres), Novo Nordisk's novelliptide (lilaluptide), Sansheng pharmaceutical, Sansheng pharmaceutical, Sansheng pharmaceutical and Shanghai Renhui biology's yishengtai (benaluptide) Table 1: in addition to GLP-1 receptor agonists approved for marketing in China, three other long-term varieties are also being declared, including Jiangsu Haosen's polyethylene glycol losenapeptide, Lilly's Dula glycopeptide, Novo Nordisk's somalutide Jiangsu Haosen has submitted the production application of pegylated losenapeptide in December 2017, or it will be approved by the end of 2018 none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box sizing: border box! Im assistant; word wrap: break word! Im assistant; "> Sansheng pharmaceutical, a rich product line under research, is a biopharmaceutical group integrating research, development, production and sales of biopharmaceuticals, and one of the first Chinese biopharmaceutical companies to enter the US stock market Subsequently, with the strategic adjustment of the group's development, it was listed in Hong Kong in 2015 after the privatization in the United States, with a current market value of nearly HK $40 billion Sansheng pharmaceutical focuses on the development of recombinant or genetically engineered protein drugs, monoclonal antibodies, to meet the clinical treatment of kidney disease, tumor, autoimmune diseases, anti organ transplant rejection and other major disease areas of drug demand In the first half of 2017, the R & D cost of Sansheng Pharmaceutical Co., Ltd was 113 million yuan, an increase of 3.7% compared with 109 million yuan in the same period of last year, accounting for 6.62% of revenue Compared with 7.56% of Fosun Pharmaceutical Co., Ltd and 4.51% of Shiyao group, Sansheng Pharmaceutical Co., Ltd is in the middle and upper reaches of the industry Table 2: Sansheng pharmaceutical has a rich product line under research At present, Sansheng pharmaceutical has more than 20 products under research, covering the fields of oncology, autoimmune diseases and other diseases, Nephrology, metabolism and dermatology, among which 16 are national first-class new drugs It is reported that clinical trials of two monoclonal antibodies, trastuzul and rituximab, have been completed Trastuzul is expected to be produced in the first half of 2018 and listed in the second half of 2018 or 2019 none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> core products keep leading in the market According to the annual report, Sansheng pharmaceutical has several core products, such as tebio, yisepu, and yibio, which continue to maintain the leading position in the domestic market Figure 1: 2014-2016 sales of terminal recombinant human thrombopoietin of public medical institutions in China (unit: 10000 yuan) tebio is a patent product independently developed by Sansheng pharmaceutical, which has become the only commercial recombinant human thrombopoietin product in the world since its launch in 2006 Tebuao has been approved for two indications: chemotherapy-induced thrombocytopenia and immunothrombocytopenic purpura According to the data of mienei.com, in 2016, the sales volume of China's public medical institutions terminals (including China's urban public hospitals, county-level public hospitals, urban community centers and township health centers) exceeded the 1 billion mark, about 1.05 billion yuan, a year-on-year increase of 25.04% In addition, the 2017 edition of the national medical insurance catalogue has cancelled the limitation of reimbursement for work-related injuries caused by thrombocytopenia caused by chemotherapy in tebiao, and it is expected that the overall sales growth rate in tebiao will increase again Figure 2: in 2016, the brand pattern of terminal recombinant human tumor necrosis factor receptor antibody fusion protein yisaipu, commonly known as etanercept, is a recombinant human tumor necrosis factor receptor antibody fusion protein, produced by the subsidiary Sansheng Guojian It was first launched in China in 2005 for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis Yisaipu has been included in the 2017 national medical insurance catalog According to the data of mienei.com, in 2016, the sales volume of China's public medical institutions terminal yisaipu reached 730 million yuan, an increase of 15.20% year on year, with a market share of 94.88%, ranking first Figure 3: Sales of terminal ProBio and saibor in public medical institutions in China in 2016 (unit: 10000 yuan) ProBio is a recombinant human erythropoietin (rhEPO) product approved by CFDA that can be used for three indications: treatment of anemia caused by chronic kidney disease, treatment of anemia caused by chemotherapy, and perioperative red blood cell mobilization Ibio has been the dominant leader in China's rhEPO market since 2002 In 2016, the terminal sales of public medical institutions in China reached 1.15 billion yuan, with a market share of 42.4% In addition, saibor is the second brand of rhEPO products of Sansheng pharmaceutical, which is produced by its subsidiary, Shenzhen saibor biopharmaceutical industry In 2016, the terminal sales of public medical institutions in China were 120 million yuan none="shifuMouseDown('shifu_t_002')" style="margin: 1em auto; padding: 0.5em 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border: none; text-align: center; width: 670px; box-sizing: border-box !im portant; word-wrap: break-word ! im assistant; "> conclusion from the information disclosed publicly by Sansheng pharmaceutical, Sansheng pharmaceutical's performance has grown steadily in recent years In the first half of 2017 alone, it realized revenue of about 1.707 billion yuan, net profit of 390 million yuan and gross profit of 1.457 billion yuan, an increase of about 30.8%, 34.3% and 28.6% compared with the same period in 2016 It must be inseparable from its several core products to achieve such gratifying performance And this time, will the listing of baidayang open a new profit source channel for Sansheng pharmaceutical? Let's wait and see!